An open-label study of the effect of Herceptin [trastuzumab] monotherapy on tumor response in women with metastatic breast cancer with HER2 [human epidermal growth factor receptor-2] overexpression/amplification
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jan 2008 Status changed from in progress to completed.
- 16 Jun 2006 New trial record.